0001604821-26-000032
SEC filingNatera第三季度营收7.94亿美元、同比增长34.1%,肿瘤检测量增长60.9%并上调全年营收指引至30.05亿至30.35亿美元。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $793.981 million | $592.183 million | 34.1% |
| Gross Margin | 64.7% | 64.9% | — |
| Operating Income | $(68.322) million | $(97.576) million | — |
| Net Income | $(59.912) million | $(87.544) million | — |
| Diluted EPS | $(0.42) | $(0.64) | — |
| Tests Processed | 1,093,100 | 893,600 | 22.3% |
| Oncology Tests Processed | 339,500 | 211,000 | 60.9% |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY2026 | Revenue | $3.005 billion - $3.035 billion | N/A |
| FY2026 | Gross Margin | approximately 64% - 66% | N/A |
| FY2026 | Selling, General and Administrative | $1.225 billion - $1.300 billion | N/A |
| FY2026 | Research and Development | $825 million - $925 million | N/A |
| FY2026 | Cash Flow | positive | N/A |
第三季度营收$794.0 million、同比增长34.1%,增长由检测量提升与平均售价改善共同驱动;肿瘤检测约339,500例、同比增长60.9%,临床MRD环比增32,700例,显示肿瘤业务是核心增量。毛利率64.7%较去年同期64.9%略降,主因收入估计变更带来的增益由3.6%降至1.5%(本期增益$32.3 million、去年同期$55.1 million);剔除该变更后非GAAP毛利率环比提升约1.4%。运营费用$576.1 million、同比增长19.5%,用于支持新产品的人员扩张与临床试验,经营亏损收窄至$68.3 million、净亏损$59.9 million。
现金及等价物与受限现金$1,097.2 million,较2025年末$1,076.1 million增加,本季现金增加约$5.7 million;总债务$80.3 million。公司将全年营收指引上调$140 million(中点)至$3.005 billion-$3.035 billion,并预计毛利率约64%-66%、经营现金流为正,显示管理层对检测量增长与定价改善的持续性有信心;本次披露未涉及回购或分红。